← Back to Clinical Trials
Recruiting NCT07079189

NCT07079189 Effect of the Digital Livsstilsverktyget in Conjunction With a Large Language Model on Glycemic Control in Patients With Type 2 Diabetes.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07079189
Status Recruiting
Phase
Sponsor Region Skane
Condition Diabetes Mellitus (Type 2)
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2025-08-11
Primary Completion 2027-05-31

Eligibility & Interventions

Sex All sexes
Min Age 35 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Lifestyle tool

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2025-08-11 with a primary completion date of 2027-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overall aim of the study is to observe the change of long-term metabolic control in patients with type 2 diabetes who have access to a digital intervention tool as compared with randomized controls during one year. The tool is based on self-affirmation theory and has large emphasis on self-reflection to enable sustainable lifestyle changes. Users get access to expert-written information about relevant health topics and interact with an LLM to promote reflection on the information.

Eligibility Criteria

Inclusion Criteria: * Patients with type 2 diabetes * Diagnosis of diabetes mellitus was based on prior documentation or treatment with anti-hyperglycemic medication * age at or above 35 years * access to Internet * informed consent Exclusion Criteria: * Treatment with insulin * Change of anti-diabetic treatment with three months prior to inclusion * Participation in other study that may affect the outcomes * Condition or treatment that in the judgement of the Investigator precludes participation * Inability to read and write in Swedish * Work in competing areas

Contact & Investigator

Central Contact

Birgitta Abrahamsson

✉ birgitta.x.abrahamsson@skane.se

📞 +46705316704

Principal Investigator

Anders Rosengren, MD PhD

PRINCIPAL INVESTIGATOR

Region Skane

Frequently Asked Questions

Who can join the NCT07079189 clinical trial?

This trial is open to participants of all sexes, aged 35 Years or older, studying Diabetes Mellitus (Type 2). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07079189 currently recruiting?

Yes, NCT07079189 is actively recruiting participants. Contact the research team at birgitta.x.abrahamsson@skane.se for enrollment information.

Where is the NCT07079189 trial being conducted?

This trial is being conducted at Malmö, Sweden.

Who is sponsoring the NCT07079189 clinical trial?

NCT07079189 is sponsored by Region Skane. The principal investigator is Anders Rosengren, MD PhD at Region Skane. The trial plans to enroll 300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology